A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine hydrochloride in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 4, 2007, Pages 447-460

  Gau, Susan S F ^a,b   Huang, Yu Shu ^c   Soong, Wei Tsuen ^a,b   Chou, Miao Chun ^c   Chou, Wen Jiun ^c   Shang, Chi Yung ^b   Tseng, Wan Ling ^b   Allen, Albert J ^d   Lee, Phil ^e,f,g  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d ELI LILLY AND COMPANY   (United States)

^e Eli and Lilly Co   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^g NONE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; ASTHENIA; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHARYNGITIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINITIS; SCHOOL CHILD; SCORING SYSTEM; SHORT FORM 36; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOM; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 34548666657     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0091     Document Type: Article

References (36)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC, American Psychiatric Association, 1994.
2. Barton J: Atomoxetine: A new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child 90 (Suppl 1): i26-i29, 2005.
3. Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ: Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 110:e75, 2002.
4. Brown WJ, Biederman J, Spencer T, Heiligenstein J, Wernicke J, Allen AJ, Faries D, Michelson D: Efficacy and safety of atomoxetine in the treatment of attention deficit/hyperactivity disorder in children and adolescents. Eur Neuropsychopharmacol 12 (Suppl 3): S411, 2002.
5. Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnston M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D, Group. SIS: A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 13:249-257, 2004.
6. Cohen J: Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale (New Jersey), Lawrence Earlbaum Associates, 1988.
7. Conners CK: Conners' Rating Scales-Revised Technical Manual. North Tonawanda (New York), Multi-Health Systems, 1997.
8. Conners CK, Sitarenios G, Parker JD, Epstein JN: The revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26:257-268, 1998a.
9. Conners CK, Sitarenios G, Parker JD, Epstein JN: Revision and restandardization of the Conners' Teacher Rating Scale (CTRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol 26:279-291, 1998b.
10. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, Guilford, 1998.
11. Faraone SV, Sergeant J, Gillberg C, Biederman J: The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry 2:104-113, 2003.
12. Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation of the ADHD rating scale as a clinician administered and scored instrument. J Atten Disord 5:39-47, 2001.
13. Gau SF, Soong WT: Psychiatric comorbidity of adolescents with sleep terrors or sleepwalking: A case-control study. Aust N Z J Psychiatry 33:734-739, 1999.
14. Gau SS, Chong MY, Chen TH, Cheng ATA: A three-year panel study of mental disorders among adolescents in Taiwan. Am J Psychiatry 162:1344-1350, 2005.
15. Gau SS, Soong WT, Chiu YN, Tsai WC: Psychometric properties of the Chinese version of the Conners' Teacher and Parent Rating Scales-Revised Short Form. J Atten Disord 9:648-659, 2006a.
16. Gau SS, Shen HY, Chow MC, S. TG, Chiu YN, Gau CS: Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol 16:286-297, 2006b.
17. Gau SS, Shen HY, Soong WT, Gau CS: An open-label, randomized, active controlled equivalent trial of OROS methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol 16:439-453, 2006c.
18. Goldman LS, Genel M, Bezman RJ, Slanetz PJ: Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 279:1100-1107, 1998.
19. Greenhill L: Attention deficit hyperactivity disorder: The stimulants. Child Adolesc Psychiatr Clin N Am 4:169-195, 1995.
20. Greenhill L, Beyer DH, Finkleson J, Shaffer D, Biederman J, Conners CK, Gillberg C, Huss M, Jensen P, Kennedy JL, Klein R, Rapoport J, Sagvolden T, Spencer T, Swanson JM, Volkow N: Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/hyperactivity disorder. J Atten Disord 6 (Suppl 1):S89-S100, 2002.
21. Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda (Maryland), United States Department of Health, Education, and Welfare, 1976.
22. Hechtman L: Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:481-498, 2000.
23. Hechtman L, Greenfield B: Long-term use of stimulants in children with attention deficit hyperactivity disorder: Safety, efficacy, and long-term outcome. Pediatr Drugs 5:787-794, 2003.
24. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF: Efficacy and safety of atomoxetine in childhood attention deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 8:45-52, 2004.
25. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 114:e1-e8, 2004.
26. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83, 2001.
27. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901, 2002.
28. MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086, 1999.
29. MTA Cooperative Group: National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113 754-761, 2004.
30. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S: Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409-432, 1996.
31. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S: An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:251-265, 2001.
32. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140-1147, 2002.
33. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J: Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 116:e74-e80, 2005.
34. Wang YF, Zheng Y, Du YS, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao HT, Williams DW, Levine LR: Atomoxetine versus methylphenidate in pediatric outpatients with attention-deficit/hyperactivity disorder: A randomized, double-blind comparison trial. Aust N Z J Psychiatry 41:222-230, 2007.
35. Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ: A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 8:647-655, 2005.
36. Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL, Wigal TL, Kollins SH, Clark TM, Mays DA, Zhang Y, Tulloch SJ: A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 9:275-289, 2005.